NESTLE HEALTH SCIENCE Products & Brands - Key Offerings and Insights

Products

Category

Product

Brand

Description

Human Microbiome-based Drugs and Diagnostics: Global Markets (BIO151B)

Vowst

This FDA-approved microbiome product that prevents recurrent Clostridioides difficile (C. diff) infection is an orally administered drug formulated with fecal microbiota spores. It is indicated for individuals 18 and older after antibacterial treatment for recurrent CDI.

This information is available for BCC Research members only.

Already a Member? Sign In Become a Member

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.